Zacks' bio-tech analyst, Jason Napadano, has placed a buy rating on AMBS with a .20 price target.
It's worth your time to check it out.
If Jason's is only half right that's still a 100% upside from the current share price although I think .20 is reasonable.
@JNapodano Your "buy rating" and .20 price target on $AMBS isn't looking so great here. Gerald's silence isn't helping. Any comment?
@wcoastguynca I have patiences. I'm not concerned with day-to-day. I'm expecting GC shareholder update very soon, along with Q4 report.